Imeik Technology Development Co

Imeik Technology Development Co Operating Cash Flow

The Operating Cash Flow of Imeik Technology Development Co (300896.SZ) as of Oct 17, 2026 is 1.39 B CNY. In the previous year, Operating Cash Flow was 1.93 B CNY — a change of -28.04% (lower).

Operating Cash Flow

1.39 BCNY

YoY

-28.04%

Last updated:

Operating Cash Flow of Imeik Technology Development Co is 2025 1.39 B CNY. Operating Cash Flow of Imeik Technology Development Co was 2024 1.93 B CNY. It decreases by -28.04% lower compared to the previous year.

The Imeik Technology Development Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
135.50 M CNY
Jan 1, 2019
309.72 M CNY
Jan 1, 2020
425.68 M CNY
Jan 1, 2021
942.78 M CNY
Jan 1, 2022
1.19 B CNY
Jan 1, 2023
1.95 B CNY
Jan 1, 2024
1.93 B CNY
Jan 1, 2025
1.39 B CNY
The Imeik Technology Development Co Operating Cash Flow history
YEAROperating Cash FlowYoY
1.39 BCNY-28.04%
1.93 BCNY-1.38%
1.95 BCNY+63.67%
1.19 BCNY+26.64%
942.78 MCNY+121.48%
425.68 MCNY+37.44%
309.72 MCNY+128.58%
135.50 MCNY+61.00%
84.16 MCNY+53.02%
55.00 MCNY+13.76%
48.35 MCNY+72.97%
27.95 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Cash Flow of Imeik Technology Development Co is 1.39 B CNY in 2025.

Operating Cash Flow of Imeik Technology Development Co changed from 1.93 B CNY to 1.39 B CNY, representing a -28.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Imeik Technology Development Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co